15,581 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the fourth quarter, Holdings Channel reports. The fund acquired 15,581 shares of the medical research company’s stock, valued at approximately $5,119,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. acquired a new stake in shares of Bio-Rad Laboratories in the third quarter valued at about $83,681,000. Wedge Capital Management L L P NC acquired a new stake in Bio-Rad Laboratories in the 4th quarter valued at about $28,740,000. Proficio Capital Partners LLC purchased a new position in Bio-Rad Laboratories in the 4th quarter worth approximately $9,820,000. DAVENPORT & Co LLC boosted its holdings in shares of Bio-Rad Laboratories by 48.8% during the 4th quarter. DAVENPORT & Co LLC now owns 84,677 shares of the medical research company’s stock worth $27,817,000 after purchasing an additional 27,780 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Bio-Rad Laboratories by 38.3% in the third quarter. The Manufacturers Life Insurance Company now owns 86,782 shares of the medical research company’s stock valued at $29,036,000 after purchasing an additional 24,052 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Royal Bank of Canada reissued an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Wells Fargo & Company dropped their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $395.20.

Bio-Rad Laboratories Price Performance

NYSE:BIO opened at $247.16 on Wednesday. The company has a market capitalization of $6.92 billion, a P/E ratio of -3.80 and a beta of 0.98. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 52 week low of $244.00 and a 52 week high of $387.99. The stock’s fifty day moving average is $299.43 and its two-hundred day moving average is $324.12.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.